518 related articles for article (PubMed ID: 32615525)
1. Repurposing old drugs to fight multidrug resistant cancers.
Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Drug Discovery By Structure-Based Repositioning Approach.
Modh DH; Kulkarni VM
Mini Rev Med Chem; 2024; 24(1):60-91. PubMed ID: 37165589
[TBL] [Abstract][Full Text] [Related]
3. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
Mottini C; Napolitano F; Li Z; Gao X; Cardone L
Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
[TBL] [Abstract][Full Text] [Related]
4. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.
Mohi-Ud-Din R; Chawla A; Sharma P; Mir PA; Potoo FH; Reiner Ž; Reiner I; Ateşşahin DA; Sharifi-Rad J; Mir RH; Calina D
Eur J Med Res; 2023 Sep; 28(1):345. PubMed ID: 37710280
[TBL] [Abstract][Full Text] [Related]
5. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions.
Tolios A; De Las Rivas J; Hovig E; Trouillas P; Scorilas A; Mohr T
Drug Resist Updat; 2020 Jan; 48():100662. PubMed ID: 31927437
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in drug repositioning for the discovery of new anticancer drugs.
Shim JS; Liu JO
Int J Biol Sci; 2014; 10(7):654-63. PubMed ID: 25013375
[TBL] [Abstract][Full Text] [Related]
7. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
[TBL] [Abstract][Full Text] [Related]
8. Drug repositioning in cancer: The current situation in Japan.
Masuda T; Tsuruda Y; Matsumoto Y; Uchida H; Nakayama KI; Mimori K
Cancer Sci; 2020 Apr; 111(4):1039-1046. PubMed ID: 31957175
[TBL] [Abstract][Full Text] [Related]
9. Drug Repurposing Strategies for Non-cancer to Cancer Therapeutics.
Singhal S; Maheshwari P; Krishnamurthy PT; Patil VM
Anticancer Agents Med Chem; 2022 Aug; 22(15):2726-2756. PubMed ID: 35301945
[TBL] [Abstract][Full Text] [Related]
10. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
11. Computational drug repositioning for cancer therapeutics.
Jiao M; Liu G; Xue Y; Ding C
Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
[TBL] [Abstract][Full Text] [Related]
12. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics.
Konreddy AK; Rani GU; Lee K; Choi Y
Curr Med Chem; 2019; 26(28):5363-5388. PubMed ID: 29984648
[TBL] [Abstract][Full Text] [Related]
13. Repurposing Marketed Drugs as Antidepressants with In Silico, In Vivo, and In Vitro Screening Methods.
Naveena P; Usha KK; Swetha M; Hemalatha M; Swathi K
Adv Exp Med Biol; 2023; 1423():271-278. PubMed ID: 37525054
[TBL] [Abstract][Full Text] [Related]
14. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
[TBL] [Abstract][Full Text] [Related]
15. In silico drug repositioning: what we need to know.
Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
[TBL] [Abstract][Full Text] [Related]
16. Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs.
Sohraby F; Aryapour H
Semin Cancer Biol; 2021 Jan; 68():249-257. PubMed ID: 32360530
[TBL] [Abstract][Full Text] [Related]
17. Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform.
Hudson ML; Samudrala R
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925237
[TBL] [Abstract][Full Text] [Related]
18. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Hsiao SH; Lusvarghi S; Huang YH; Ambudkar SV; Hsu SC; Wu CP
Cancer Lett; 2019 Mar; 445():34-44. PubMed ID: 30639533
[TBL] [Abstract][Full Text] [Related]
19. Modulating ROS to overcome multidrug resistance in cancer.
Cui Q; Wang JQ; Assaraf YG; Ren L; Gupta P; Wei L; Ashby CR; Yang DH; Chen ZS
Drug Resist Updat; 2018 Nov; 41():1-25. PubMed ID: 30471641
[TBL] [Abstract][Full Text] [Related]
20. Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer.
Shankaraiah N; Nekkanti S; Ommi O; P S LS
Curr Med Chem; 2019; 26(39):7059-7080. PubMed ID: 29637849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
